Early data from US biotech Moderna has revealed that its Covid-19 vaccine candidate is 94.5 per cent effective, raising hopes that a range of immunisations will be available to help end the pandemic.
The interim analysis of the vaccine, currently known as mRNA-1273, comes after 95 trial participants contracted Covid-19, including just five who were given the coronavirus jab.
While the data was published via a press release, it includes significant details that remain unclear around the Pfizer-BioNTech vaccine – which uses the same mRNA technology to target the coronavirus spike protein and an immune response.
Subscribe to The Telegraph on YouTube ►
Read more about the new coronavirus vaccine:
Telegraph.co.uk and YouTube.com/TelegraphTV are websites of The Telegraph, the UK’s best-selling quality daily newspaper providing news and analysis on UK and world events, business, sport, lifestyle and culture.
